ERBB2 and breast cancer: Specifically, in the 2015–2019 diagnostic period, HER2+/HR+ BC had the highest 5-year overall survival (86.5%, 95% CI: 85.0% - 88.0%), while TNBC had the poorest (61.4%, 95% CI: 59.6%-63.2%).